No matter the m 1 A modification actually occurs on SARS-CoV-2 genome or not, the finding that m 1 A severely inhibits SC2RC of the virus may provide alternative strategies to combat COVID-19. For example, for the general population, methods to elevate methyltransferases without elevate demethylases could be considered. For people with clinical conditions such as cancer, obesity and diabetes, methods to lower demethylases would be a logical consideration. In addition, if genetic information regarding the likelihood of a population or individual to upregulate methyltransferases and downregulate demethylases responsible for the m 1 A modification becomes available in the future, the response of the population or individual to SARS-CoV-2 could become more predictable.